Drugs / candesartan / hydrochlorothiazide
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00000620 Background | Sep 1999 → Jun 2009 | atherosclerosis, coronary artery disorder, hyperlipoproteinemia, hypertensive disorder +1 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | candesartan / hydrochlorothiazide | “candesartan / hydrochlorothiazide (Atacand HCT)” NCT00000620 ↗ |
| Known as | candesartan / hydrochlorothiazide (Atacand HCT) | “candesartan / hydrochlorothiazide (Atacand HCT)” NCT00000620 ↗ |